rais
edward post mix result tuesday close miss us tavr
busi overshadow top bottom-lin beat ep guidanc
rais sale report organ came higher
consensu stronger surgic heart valv critic
global transcathet valv sale miss grew
full year guidanc growth geograph tavr sale longer
provid estim us tavr grew miss street
ou grew beat balanc year
manag reiter revenu guidanc high end
rais ep guidanc vs
beat impli reduct ep vs street balanc
year ep guidanc street
estim exit reiter neutral rate ew ww tavr growth
need acceler averag hit growth
vs guidanc jpme level growth possibl
requir better market growth and/or share gain get would
repres revers recent trend
quarter global transcathet valv sale came
consensu repres expect sequenti deceler
growth seen market continu slow
ahead low risk data fell short expect growth
estim us tavr sale quarter vs street
ou sale grow report
consensu us market edward procedur growth grew
mid-teen outsid us market procedur growth low
double-digit edward gain share y/i
look forward question tavr busi growth bottom
ahead low risk data full year model us tavr
market grow declin saw still better
expect head year rememb recent survey point
toward us tavr volum growth number see encourag
one take grain salt given higher volum growth respond
saw center
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
forecast edward ww transcathet valv sale
see edward grow number full year tavr sale
us look ou expect continu strong procedur
growth europ grow japan grow final
transcathet estim also includ contribut cardioband
look back balanc busi edward non-tavr segment also
beat across board surgic heart valv sale beat
mid-singl digit unit growth heart valv off-set mid-singl digit
declin repair segment strong uptak intuiti elit us continu
particularli benefit new tech add-on payment start
octob recent launch inspiri resilia start edward switch
consign inventori model surgic heart valv expect help
better introduc new product manag inventori result sale
return reserv adjust year exclud
adjust sale critic system sale
particularli strong beat strong sale hemospher edward next-gen
look gross margin came street call
headwind fx continu invest back busi
lower tavr mix hand sg came
better expect led beat oper margin edward also
benefit signific below-the-lin item benefit posit
interest expens benefit vs headwind coupl
benefit tax vs told led cash ep
quarter consensu
edward provid sever updat pipelin receiv ce mark approv
self-expand centera valv februari edward launch valv
premium price sapien europ saw minim revenu contribut
quarter compani also recent receiv approv centera us pivot trial
patient single-arm studi measur one-year endpoint
sapien ultra despit unexpect requir clinic trial supplement ce
mark submiss ew expect eu approv us approv
european data fulli enrol edward receiv approv
continu access protocol cap continu implant low-risk patient certain
site us program begin provid slight tailwind
us tavr sale transcathet mitral tricuspid arena updat
provid harpoon manag continu expect eu launch
cardioband expect ramp less
first quarter pascal expect launch europ begin us
trial cardioband tr complet ce mark enrol
track eu launch later year upcom europcr confer
see earli cardioband data mitral tricuspid applic
manag reiter revenu guidanc across board rais ep
less size beat balanc year manag reiter
revenu guidanc high end rais ep
guidanc vs beat impli
reduct ep vs street balanc year ep guidanc
also fall street estim revenu
expect rang in-lin street
invest thesi valuat risk
edward post solid start year still believ stock remain
stori revenu grow ep investor
like look forward releas edward medtron
risk tavr trial march compani transcathet mitral
tricuspid repair program begin ramp meaning contribut top-lin
perform first time therefor transit year albeit project
top-lin bottom-lin growth come risk howev
tavr market slow last sever quarter like slow
get risk trial fulli expect posit therefor
catalyst absent top-lin upsid meaning pipelin catalyst next
month think edward shape stori investor
want revisit later year remain neutral
dec price target valu share ep estim
repres signific premium current large-cap med-tech averag
ntm ep believ premium justifi given edward differenti
outlook top bottom line
risk rate price
upsid risk rate includ better-than-expect tavr growth competitor
pipelin product failur better-than-expect critic perform
favor chang tavr procedur reimburs particularli intern
downsid risk rate includ increas competit us
clinic trial result setback compani transcathet mitral program
edward lifesci summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect person view subject secur issuer part
research analyst compens directli indirectli relat specif recommend view
express research analyst report korea-bas research analyst list front cover also certifi per
kofia requir analysi made good faith view reflect opinion without undu influenc
